These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 26276891)

  • 1. Transcriptional Profiling of Breast Cancer Metastases Identifies Liver Metastasis-Selective Genes Associated with Adverse Outcome in Luminal A Primary Breast Cancer.
    Kimbung S; Johansson I; Danielsson A; Veerla S; Egyhazi Brage S; Frostvik Stolt M; Skoog L; Carlsson L; Einbeigi Z; Lidbrink E; Linderholm B; Loman N; Malmström PO; Söderberg M; Walz TM; Fernö M; Hatschek T; Hedenfalk I;
    Clin Cancer Res; 2016 Jan; 22(1):146-57. PubMed ID: 26276891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Claudin-2 is an independent negative prognostic factor in breast cancer and specifically predicts early liver recurrences.
    Kimbung S; Kovács A; Bendahl PO; Malmström P; Fernö M; Hatschek T; Hedenfalk I
    Mol Oncol; 2014 Feb; 8(1):119-28. PubMed ID: 24287398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.
    Schroth W; Winter S; Büttner F; Goletz S; Faißt S; Brinkmann F; Saladores P; Heidemann E; Ott G; Gerteis A; Alscher MD; Dippon J; Schwab M; Brauch H; Fritz P
    Breast Cancer Res Treat; 2016 Jan; 155(1):85-97. PubMed ID: 26650824
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrasting breast cancer molecular subtypes across serial tumor progression stages: biological and prognostic implications.
    Kimbung S; Kovács A; Danielsson A; Bendahl PO; Lövgren K; Frostvik Stolt M; Tobin NP; Lindström L; Bergh J; Einbeigi Z; Fernö M; Hatschek T; Hedenfalk I
    Oncotarget; 2015 Oct; 6(32):33306-18. PubMed ID: 26375671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A specific gene expression signature for visceral organ metastasis in breast cancer.
    Savci-Heijink CD; Halfwerk H; Koster J; Horlings HM; van de Vijver MJ
    BMC Cancer; 2019 Apr; 19(1):333. PubMed ID: 30961553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PPFIA1 is upregulated in liver metastasis of breast cancer and is a potential poor prognostic indicator of metastatic relapse.
    Yang J; Wu NN; Huang DJ; Luo YC; Huang JZ; He HY; Lu HL; Song WL
    Tumour Biol; 2017 Jul; 39(7):1010428317713492. PubMed ID: 28720060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. β-catenin-independent WNT signaling and Ki67 in contrast to the estrogen receptor status are prognostic and associated with poor prognosis in breast cancer liver metastases.
    Bleckmann A; Conradi LC; Menck K; Schmick NA; Schubert A; Rietkötter E; Arackal J; Middel P; Schambony A; Liersch T; Homayounfar K; Beißbarth T; Klemm F; Binder C; Pukrop T
    Clin Exp Metastasis; 2016 Apr; 33(4):309-23. PubMed ID: 26862065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
    Sanpaolo P; Barbieri V; Genovesi D
    Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population-based molecular prognosis of breast cancer by transcriptional profiling.
    Ma Y; Qian Y; Wei L; Abraham J; Shi X; Castranova V; Harner EJ; Flynn DC; Guo L
    Clin Cancer Res; 2007 Apr; 13(7):2014-22. PubMed ID: 17404081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
    Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
    Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PAM50 Provides Prognostic Information When Applied to the Lymph Node Metastases of Advanced Breast Cancer Patients.
    Tobin NP; Lundberg A; Lindström LS; Harrell JC; Foukakis T; Carlsson L; Einbeigi Z; Linderholm BK; Loman N; Malmberg M; Fernö M; Czene K; Perou CM; Bergh J; Hatschek T;
    Clin Cancer Res; 2017 Dec; 23(23):7225-7231. PubMed ID: 28972041
    [No Abstract]   [Full Text] [Related]  

  • 12. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
    Zhang HM; Zhang BN; Xuan LX; Zhao P
    Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prognostic significance of computerised tomography findings in women with liver metastases from breast cancer.
    Mhlanga JC; Evans AE; Doyle S; James JJ; Cornford EJ; Balls G; Chan SY; Ellis I
    Breast; 2011 Oct; 20(5):455-9. PubMed ID: 21596564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A hedgehog pathway-dependent gene signature is associated with poor clinical outcomes in Luminal A breast cancer.
    Rudolph M; Sizemore ST; Lu Y; Teng KY; Basree MM; Reinbolt R; Timmers CD; Leone G; Ostrowski MC; Majumder S; Ramaswamy B
    Breast Cancer Res Treat; 2018 Jun; 169(3):457-467. PubMed ID: 29464534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patterns of relapse and metastatic spread in HER2-overexpressing breast cancer according to estrogen receptor status.
    Park YH; Lee S; Cho EY; Choi YL; Lee JE; Nam SJ; Yang JH; Ahn JS; Im YH
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):507-16. PubMed ID: 19956951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
    Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic factors in patients with metastatic breast cancer at the time of diagnosis.
    Ren Z; Li Y; Hameed O; Siegal GP; Wei S
    Pathol Res Pract; 2014 May; 210(5):301-6. PubMed ID: 24635972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification and clinical validation of a multigene assay that interrogates the biology of cancer stem cells and predicts metastasis in breast cancer: A retrospective consecutive study.
    Pece S; Disalvatore D; Tosoni D; Vecchi M; Confalonieri S; Bertalot G; Viale G; Colleoni M; Veronesi P; Galimberti V; Di Fiore PP
    EBioMedicine; 2019 Apr; 42():352-362. PubMed ID: 30846393
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy.
    Chen S; Huang L; Chen CM; Shao ZM
    Oncotarget; 2015 Jul; 6(20):18174-82. PubMed ID: 26053183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.
    Wiens AL; Martin SE; Bertsch EC; Vance GH; Stohler RA; Cheng L; Badve S; Hattab EM
    Arch Pathol Lab Med; 2014 Feb; 138(2):175-81. PubMed ID: 24476516
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.